Aug. 22, 2023
Targeting 20-HETE/GPR75 via Selective CYP Inhibition: A 20+ Year-Old Kidney Program from Taisho
TP0472993
oral 20-hydroxyeicosatetraenoic acid synthesis inhibitor preclinical efficacy in mouse kidney fibrosis model from in-house screen and optimization J. Pharm. Exp. Ther., May 4, 2023 Taisho Pharmaceutical CO., JP
Author:
Editor:
Loading...
